SEC Filing Summary
Filing identity: The supplied filing is Organovo Holdings, Inc. (Nasdaq: ONVO), not Vivosim Labs, Inc. It is a Form 10-Q for the quarter ended June 30, 2023 (the first quarter of fiscal 2024), filed August 10, 2023. This does not match the request metadata identifying Vivosim Labs and 2022 Q1.
Business context and reporting period
Organovo is a biotechnology company developing 3D human tissue and disease models to support drug discovery, currently focused mainly on inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. In March 2023, it acquired Metacrine’s FXR program, including two clinically tested compounds and more than 2,000 discovery or preclinical compounds.
Financial results and liquidity
| Metric | Three months ended June 30, 2023 | Comparable 2022 period |
|---|---|---|
| Revenue | $75,000, entirely royalty revenue | $0 |
| Research and development expense | $1.666 million | $1.020 million |
| Selling, general and administrative expense | $2.604 million | $2.219 million |
| Net loss | $4.028 million | $3.215 million |
| Net loss per share | $0.46 | $0.37 |
| Net cash used in operating activities | $5.311 million | $2.414 million |
At June 30, 2023, cash and cash equivalents were $10.754 million, including approximately $5.0 million invested in U.S. Treasury bills; restricted cash was $143,000. Working capital was $9.9 million, down from $13.3 million at March 31, 2023. Total liabilities were $2.980 million, including $1.705 million of operating lease liabilities. The filing reports no cash financing activities during the quarter and no conventional borrowing balance. Gross margin is not presented; with only $75,000 of royalty revenue and no reported cost of revenue, a meaningful margin comparison is not provided.
Material changes versus the prior comparable period
- Revenue increased from zero to $75,000, from sales-based royalties under the BICO patent license.
- R&D expense rose 63%, which management attributed primarily to increased staffing and research activity; average R&D headcount increased from 14 to 18.
- SG&A expense increased 17%, principally due to legal, corporate and consulting expenses.
- Net loss increased by $813,000. Operating cash use increased by $2.897 million; management cited higher R&D activity and identified $2.0 million of cash outflows related to acquired Metacrine in-process R&D.
- Cash and cash equivalents decreased from $15.301 million at March 31, 2023 to $10.754 million at June 30, 2023.
Outlook, risks and unusual items
- Management expects fiscal 2024 operating expenses of $12 million to $14 million and intends to increase R&D activity.
- The filing concludes that substantial doubt exists about the company’s ability to continue as a going concern for at least one year after the financial statements are issued. Management says substantial additional funding is needed; financing may not be available on acceptable terms. The filing also contains risk-factor language stating existing cash is expected to cover projected requirements for at least 12 months, a point investors should reconcile with the formal going-concern conclusion.
- Potential funding sources include equity, debt, grants and collaborations. The company reported approximately $28.3 million remaining under its ATM program and approximately $100 million available under its shelf registration, but also disclosed that its public float was below $75 million, limiting primary shelf offerings to one-third of public float in any 12-month period. Equity financing could dilute shareholders; debt could impose payment obligations and restrictions.
- Revenue depends on a single licensee. The company received $75,000 in royalties this quarter; this is not evidence of a diversified or material recurring revenue base.
- No legal contingency accrual was recorded, and management did not identify an unfavorable outcome as probable or reasonably possible or estimate a loss range. The filing notes that legal outcomes remain uncertain.
- Management reported disclosure controls and procedures were effective and no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Confirm the issuer and period: the filing is Organovo Holdings’ June 30, 2023 quarter, not Vivosim Labs’ 2022 Q1.
- Assess the going-concern conclusion against cash on hand, operating cash use, the fiscal-year expense outlook and the company’s actual financing access.
- Track progress and costs for the IBD programs and the acquired Metacrine FXR assets, including whether the assets produce development milestones, partnerships or revenue.
- Review subsequent royalty receipts and the status and concentration of the BICO license relationship.
- Evaluate potential shareholder dilution, including ATM or other equity issuance and the 2.709 million shares reported as reserved or issuable under equity awards and plans.